Last reviewed · How we verify

NCT03814369

AmplifEYE Colonoscopy vs Standard Colonoscopy

Completed NA Last updated 26 March 2019
What this trial tests

NA trial testing AmplifEYE in Colon Polyp in 355 participants. Completed in 30 November 2018.

Timeline
1 March 2017
Primary endpoint
30 June 2018
30 November 2018

Quick facts

Lead sponsorQueen Elizabeth Hospital, Hong Kong
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposescreening
Enrollment355
Start date1 March 2017
Primary completion30 June 2018
Estimated completion30 November 2018
Sites1 location across Hong Kong

Drugs / interventions tested

Conditions studied

Sponsor

Queen Elizabeth Hospital, Hong Kong

Who can join

Adults 50 to 79, any sex, with Colon Polyp or Adenoma Colon. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Colonoscopy screening is proven to reduce mortality rates for colorectal cancer, which relies on early detection and removal of colonic polyps. AmplifEYE is a FDA-approved device with a row of flexible detection arms attached to the tip of colonoscope which can separate colonic folds during scope withdrawal and is believed to improve polyp detection. Real-life clinical data on this relatively new device is lacking and this study aims to compare the adenoma and polyp detection rates in AmplifEYE-assisted colonoscopy versus standard colonoscopy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Colon Polyp

Currently open trials in the same condition.

Other Queen Elizabeth Hospital, Hong Kong trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03814369.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing